Teleflex (NYSE:TFX) Price Target Raised to $145.00

Teleflex (NYSE:TFX) had its price target raised by Mizuho from $140.00 to $145.00 in a research note released on Wednesday,Benzinga reports. They currently have a neutral rating on the medical technology company’s stock.

TFX has been the subject of several other research reports. Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $140.00 to $160.00 in a research report on Monday, June 8th. Bank of America raised shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective for the company in a research note on Monday, April 13th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a report on Wednesday, June 24th. Truist Financial reaffirmed a “hold” rating and issued a $143.00 target price (up from $135.00) on shares of Teleflex in a research report on Monday, May 11th. Finally, Zacks Research upgraded Teleflex from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $148.00.

Teleflex Price Performance

TFX stock opened at $134.96 on Wednesday. The stock has a market capitalization of $5.97 billion, a price-to-earnings ratio of -5.92, a price-to-earnings-growth ratio of 1.01 and a beta of 0.82. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. Teleflex has a 52-week low of $100.18 and a 52-week high of $139.67. The stock’s fifty day simple moving average is $130.48 and its 200-day simple moving average is $120.49.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The firm had revenue of $548.30 million for the quarter, compared to the consensus estimate of $536.91 million. During the same period in the prior year, the business posted $1.44 earnings per share. The firm’s revenue for the quarter was up 32.3% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Equities research analysts expect that Teleflex will post 6.7 EPS for the current year.

Teleflex Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Monday, May 25th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.0%. The ex-dividend date was Friday, May 22nd. Teleflex’s payout ratio is currently -5.96%.

Hedge Funds Weigh In On Teleflex

Hedge funds have recently made changes to their positions in the business. Banque Cantonale Vaudoise increased its holdings in Teleflex by 82.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 113 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of Teleflex in the fourth quarter worth about $37,000. UMB Bank n.a. boosted its position in shares of Teleflex by 57.1% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after buying an additional 113 shares during the period. Sound Income Strategies LLC acquired a new stake in shares of Teleflex in the fourth quarter valued at about $45,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Teleflex in the fourth quarter valued at about $45,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.